Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Financing Activities (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Cash from Financing Activities for 13 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 47.19% year-over-year to $2.6 million, compared with a TTM value of $8.7 million through Dec 2025, down 39.93%, and an annual FY2025 reading of $8.7 million, down 39.93% over the prior year.
  • Cash from Financing Activities was $2.6 million for Q4 2025 at Agios Pharmaceuticals, down from $4.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $7.3 million in Q1 2021 and bottomed at -$503.5 million in Q2 2021.
  • Average Cash from Financing Activities over 5 years is -$36.7 million, with a median of $1.2 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities plummeted 7379.15% in 2021, then soared 3750.0% in 2023.
  • Year by year, Cash from Financing Activities stood at -$18.6 million in 2021, then soared by 100.12% to $22000.0 in 2022, then skyrocketed by 3750.0% to $847000.0 in 2023, then soared by 471.66% to $4.8 million in 2024, then tumbled by 47.19% to $2.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for AGIO at $2.6 million in Q4 2025, $4.4 million in Q3 2025, and $65000.0 in Q2 2025.